Effective tax rates for the 10 largest pharma MNEs and their implications for U.S. international tax reform by Thomas Horst
By: Horst, Thomas
.
Material type: 
ArticlePublisher: 2020Subject(s): EMPRESAS MULTINACIONALES | EMPRESAS FARMACEUTICAS | IMPUESTOS | ESTADOS UNIDOS
In:
Tax Notes International v. 100, n. 12, December 21, 2020, p. 1683-1694Summary: In this article, the author analyzes financial data and effective tax rates for the largest U.S. and international multinational pharmaceutical corporations and considers the implications of those statistical results for U.S. tax reform.
| Item type | Current location | Home library | Call number | Status | Date due | Barcode |
|---|---|---|---|---|---|---|
| Artículos | IEF | IEF | OP 138-B/2020/100/12-3 (Browse shelf) | Available | OP 138-B/2020/100/12-3 |
Browsing IEF Shelves Close shelf browser
| No cover image available | No cover image available | No cover image available | No cover image available | No cover image available | No cover image available | No cover image available | ||
| OP 138-B/2020/100/11-4 Modernizing general consumption taxes in the Caribbean | OP 138-B/2020/100/12-1 U.S. tax review | OP 138-B/2020/100/12-2 Facebook, the IRS, and the commensurate with income standard | OP 138-B/2020/100/12-3 Effective tax rates for the 10 largest pharma MNEs and their implications for U.S. international tax reform | OP 138-B/2020/100/7-1 U.S. tax review | OP 138-B/2020/100/7-2 Journalists release FinCEN files as U.S. officials mull anti-money-laundering rules | OP 138-B/2020/100/8-1 Building a blockchain for the EU VAT |
Disponible también en formato electrónico.
Resumen.
In this article, the author analyzes financial data and effective tax rates for the largest U.S. and international multinational pharmaceutical corporations and considers the implications of those statistical results for U.S. tax reform.
Click on an image to view it in the image viewer
There are no comments for this item.